NHS Introduces Injectable Cancer Treatment to Cut Hospital Time

NHS cancer jab could save patients – The National Health Service (NHS) in the UK is set to roll out an innovative injectable version of a vital cancer medication, offering patients the potential to significantly reduce their time spent in hospitals. This new method could benefit thousands of individuals undergoing treatment for various cancers, streamlining procedures and improving convenience. The drug in question, Keytruda, has already proven effective in treating multiple forms of the disease, but its traditional administration via intravenous drip has long been time-consuming, often requiring more than an hour per session.

A Shift in Administration

Keytruda, an immunotherapy medication, functions by aiding the body’s immune system in identifying and attacking cancer cells. Until recently, patients in the NHS received the drug through a slow infusion process, which involved preparing a sterile solution in a hospital pharmacy and delivering it via a cannula into the vein. This method, while effective, has placed a strain on healthcare resources and limited patient mobility during treatment. NHS England has now announced the introduction of a new injectable format, which is expected to cut the administration time to just a few minutes. This change could free up space in chemotherapy units and pave the way for more outpatient care options.

Shirley Xerxes, an 86-year-old patient from St Albans in Hertfordshire, was among the first to try the new injectable form at the Mount Vernon Cancer Centre near Watford. She described the experience as a “game-changer,” noting how the procedure had transformed her routine. “I was in the chair for just minutes instead of an hour or more,” she said. “It’s made such a difference and gives me more time to live my life, including spending more time gardening.” Her testimonial highlights the practical benefits of the streamlined approach, particularly for elderly patients who may struggle with lengthy hospital stays.

Expanding Access and Efficiency

NHS England estimates that approximately 14,000 cancer patients in England begin treatment with Keytruda annually. The switch to the injectable form is anticipated to be adopted by the majority of these patients, reducing the burden on hospital facilities. The drug’s versatility allows it to treat 14 distinct cancer types within the UK, such as lung, head and neck, cervical, and breast cancers. The new method offers two administration schedules: a one-minute injection every three weeks or a two-minute injection every six weeks, tailored to the specific diagnosis of each patient.

This development marks the third immunotherapy drug to be introduced in an injectable format on the NHS. Following the launch of Opdivo (nivolumab) in some hospitals last year, Keytruda’s new version represents a significant step forward in treatment accessibility. The shift from infusions to injections is expected to ease the workload for healthcare staff, who currently spend considerable time preparing and delivering the drug. With this change, the NHS aims to make cancer care more efficient and patient-friendly.

Scientific Breakthrough Behind Immunotherapy

The mechanism of immunotherapy, which Keytruda exemplifies, hinges on the body’s ability to recognize and combat cancer cells. Cancer often evades detection by producing proteins that act as a “stop signal” for immune cells, effectively cloaking itself from the body’s defenses. This phenomenon, likened to an “invisibility cloak” by some researchers, is a key target for immunotherapy. By blocking these signals, the treatment enables the immune system to identify and destroy cancer cells more effectively. This scientific breakthrough was recognized with the 2018 Nobel Prize in Medicine, awarded to James Allison and Tasuku Honjo for their pioneering work.

Keytruda was among the first immunotherapy drugs to gain approval, initially used for skin cancer before expanding to other malignancies. Its global success has made it the most commercially successful prescription medicine in the world, with sales exceeding $30 billion in 2025 alone. Since its launch over a decade ago, the drug’s cumulative sales are projected to reach $180 billion, underscoring its widespread impact. However, the NHS faces challenges as the original patents for Keytruda are set to expire in 2028 in the US and 2031 in Europe, potentially allowing competitors to develop cost-effective generic alternatives.

Cost Considerations and Strategic Motivations

While NHS England has not disclosed the exact cost of the new injectable version, sources suggest it will align with the price of the existing infusion method. This parity in cost is notable, as the switch is primarily driven by operational efficiency rather than financial savings. The decision to introduce the jab is also strategic, as it addresses the growing demand for outpatient care. Prof Peter Johnson, NHS England’s national clinical director for cancer, emphasized the benefits of the new format. “Managing cancer treatment and regular hospital visits can be exhausting,” he explained. “Shortening the administration time allows us to focus on delivering care in community settings, reducing reliance on hospital infrastructure.”

MSD, the US pharmaceutical company behind Keytruda, has positioned the injectable version as a way to enhance hospital workflows. The new formulation is covered by different patents, which some critics argue may be a tactic to delay the entry of generic competitors. Democratic Senator Elizabeth Warren has previously accused MSD of leveraging the patent system to maintain high prices and protect market dominance. Despite this, MSD maintains that the jab provides meaningful advantages, including reduced administration time, improved resource allocation, and decreased pressure on NHS facilities.

For patients like Shirley Xerxes, the change has already brought tangible improvements. The ability to receive treatment quickly not only saves time but also reduces the stress associated with frequent hospital visits. This shift reflects a broader trend in healthcare towards decentralizing treatment and prioritizing patient-centered care. As the NHS continues to adapt, the injectable version of Keytruda stands as a testament to the evolving landscape of cancer therapy, balancing innovation with practicality.